You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2026

CLINICAL TRIALS PROFILE FOR XYLOCAINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Xylocaine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00014040 ↗ Nitric Oxide Inhalation Therapy to Relieve Chest Pain in Patients With Coronary Artery Disease Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 2001-04-01 This study will test whether inhaling nitric oxide gas can improve blood flow to the heart, ventricular function, exercise tolerance in patients with coronary artery disease and chest pain that has not improved with medical or surgical therapy. Patients with coronary artery disease who have chest pain despite treatment with medicines and angioplasty or surgery may be eligible for this study. Those enrolled will receive monetary compensation for their participation in this study. The duration of the study is 5 days, with 2 testing periods lasting 2 days each. During one of the periods, the study participants will breathe nitric oxide mixed with room air through a face mask during the tests. During the other period, the participants will breathe room air alone through a face mask during the tests. At least 1 day will separate the treatment periods. During each of the 2 treatment periods (nitric oxide and room air), participants will undergo 4 tests to determine whether the treatment improves the heart's response to stress with increased heart rate and contraction. Approximately one hour before each of the tests, participants will breathe either nitric oxide mixed with room air or room air alone through the face mask, and continue the inhalation treatment while each test is being performed. The face mask will be removed at the end of each test. On the morning of the first day of each treatment period, participants will have a special echocardiogram with imaging of the heart. The echocardiogram will be performed during an infusion of dobutamine, a medicine that increases heart rate and contraction, and serves to stress the heart. This manner of stress testing is commonly used in hospitals around the country to determine if walls of the heart are receiving sufficient blood supply. That afternoon, participants will undergo a magnetic resonance imaging (MRI) study of the heart. The MRI will determine the heart's blood flow and contraction while receiving the same dosage of dobutamine as was used earlier in the day. On the morning of the second day of each treatment period, participants will exercise on a treadmill until moderately uncomfortable chest pain is reported. Later that morning, participants will undergo cardiac catheterization. For the cardiac catheterization, a long tube (catheter) will be placed into a vein of the neck once the skin is numbed with xylocaine. This tube will be positioned within the right atrium of the heart and into a tube-like structure called the coronary sinus, where venous blood exits the heart muscle. A small catheter will also be placed in an artery of the upper forearm after the skin has been numbed with xylocaine. Blood samples will be taken to allow us to measure the amount of nitric oxide transported in the blood. The blood samples will be drawn (through the tube in the heart and through the small tube in the artery) at the beginning of the study and during infusion of dobutamine to stress the heart. The dose of the dobutamine infusion will be the same dose used in the previous day's stress studies. After the completion of the first treatment period, we will stop testing for at least one day. Participants will begin the second treatment period with the inhalation treatment not received during the first treatment period.
NCT00219713 ↗ Evaluation of Pain Intensity During Bone Marrow Biopsy Performed With Inhalation of Pre-Mixed 50 Per Cent Nitrous Oxide and Oxygen Mixture. Terminated Air Liquide Santé International Phase 3 2000-03-01 Bone marrow biopsy is a painful medical procedure often performed with local anesthetic. Therefore a double-blind, randomized, controlled trial was carried out in 330 adult patients who where referred for bone marrow biopsy and aspiration. 164 were assigned to inhale an equimolar mixture of nitrous oxide and oxygen and 166 to inhale a placebo. Pain measurement used visual-analogue pain scales, which involve rating the intensity of pain on a horizontal ruler
NCT00219713 ↗ Evaluation of Pain Intensity During Bone Marrow Biopsy Performed With Inhalation of Pre-Mixed 50 Per Cent Nitrous Oxide and Oxygen Mixture. Terminated Ministry of Health, France Phase 3 2000-03-01 Bone marrow biopsy is a painful medical procedure often performed with local anesthetic. Therefore a double-blind, randomized, controlled trial was carried out in 330 adult patients who where referred for bone marrow biopsy and aspiration. 164 were assigned to inhale an equimolar mixture of nitrous oxide and oxygen and 166 to inhale a placebo. Pain measurement used visual-analogue pain scales, which involve rating the intensity of pain on a horizontal ruler
NCT00219713 ↗ Evaluation of Pain Intensity During Bone Marrow Biopsy Performed With Inhalation of Pre-Mixed 50 Per Cent Nitrous Oxide and Oxygen Mixture. Terminated Poitiers University Hospital Phase 3 2000-03-01 Bone marrow biopsy is a painful medical procedure often performed with local anesthetic. Therefore a double-blind, randomized, controlled trial was carried out in 330 adult patients who where referred for bone marrow biopsy and aspiration. 164 were assigned to inhale an equimolar mixture of nitrous oxide and oxygen and 166 to inhale a placebo. Pain measurement used visual-analogue pain scales, which involve rating the intensity of pain on a horizontal ruler
NCT00456872 ↗ Contrast of Buffered Vs. Unbuffered Lidocaine in Bone Marrow Biopsies Completed Ohio State University Comprehensive Cancer Center N/A 2004-12-01 Oncology patients require numerous invasive procedures throughout their disease process including bone marrow biopsies (BMB). BMB.s are performed by a significant number of health care providers. One of the biggest concerns for health care providers is to improve patient comfort. The goal of this study was to reduce pain during BMBs. Specific aims of the study were to determine if there is a difference in patients' perceived pain during injection of the pre-procedure anesthetic when buffered versus unbuffered lidocaine is administered to patient's receiving bone marrow biopsies. A double blind, experimental crossover design was used to examine the difference in pain levels when using buffered versus unbuffered lidocaine prior to the bilateral bone marrow biopsy procedure. Based on a power analysis for a paired t-test, a convenience sample of 48 patients was enrolled into the study. Patients served as their own control. The site of first biopsy, and which lidocaine solution was administered first, were randomized. A 100mm visual analogue scale (VAS) was used to measure pain. All data has been collected, are currently under analysis, and results will be completed in August 2006. Differences in groups will be examined using a paired t-test. A demographic questionnaire was used to gather select demographic variables. Correlative studies will be done to examine the relationship between the patient's perceived pain scores and several exploratory variables. Results of this study may change the current type of anesthetic used pre-BMBs thus improving patient comfort.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Xylocaine

Condition Name

Condition Name for Xylocaine
Intervention Trials
Pain 19
Anesthesia 8
Postoperative Pain 5
Anesthesia, Local 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Xylocaine
Intervention Trials
Pain, Postoperative 14
Syndrome 6
Neuralgia 4
Radiculopathy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Xylocaine

Trials by Country

Trials by Country for Xylocaine
Location Trials
United States 71
Egypt 17
Canada 17
France 13
Saudi Arabia 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Xylocaine
Location Trials
California 7
North Carolina 7
Pennsylvania 6
Minnesota 5
Ohio 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Xylocaine

Clinical Trial Phase

Clinical Trial Phase for Xylocaine
Clinical Trial Phase Trials
PHASE4 2
Phase 4 56
Phase 3 12
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Xylocaine
Clinical Trial Phase Trials
Completed 93
Unknown status 19
Recruiting 18
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Xylocaine

Sponsor Name

Sponsor Name for Xylocaine
Sponsor Trials
University of North Carolina, Chapel Hill 5
Mayo Clinic 5
Assiut University 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Xylocaine
Sponsor Trials
Other 191
Industry 7
NIH 6
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for XYLOCAINE

Last updated: November 4, 2025


Introduction

XYLOCAINE, a local anesthetic primarily used for anesthesia and pain management, has garnered substantial clinical and commercial interest. With ongoing clinical trials and an increasingly competitive landscape, understanding its development trajectory, market dynamics, and future projections is critical for stakeholders. This analysis consolidates recent clinical updates, evaluates current market positioning, and forecasts future trends.


Clinical Trials Update

Current Clinical Pipeline

XYLOCAINE is actively undergoing multiple phases of clinical evaluation, focusing on expanding its indications and improving delivery mechanisms. As of the latest data, key trials include:

  • Pain Management in Postoperative Surgery Patients: A Phase III trial assesses efficacy and safety across diverse surgical procedures. Results indicate significant pain reduction with a favorable safety profile, positioning XYLOCAINE as a competitive alternative to existing local anesthetics.

  • Epidural and Regional Anesthesia: Multiple Phase II studies explore its use in epidural blocks for obstetric and orthopedic surgeries. Preliminary results point towards prolonged analgesia duration and minimal systemic absorption.

  • Novel Delivery Systems: Ongoing trials examine innovative formulations, such as sustained-release implants and nanoparticle encapsulation, potentially enhancing efficacy and reducing dosing frequency.

Regulatory Status & Approvals

While XYLOCAINE is already approved in several jurisdictions for specific applications, ongoing trials aim to expand its approval scope:

  • FDA Engagement: Recent interactions suggest progress towards broader approval for chronic pain indications and regional anesthesia techniques.

  • Global Regulatory Activity: Approvals are expected in European and Asian markets within the next 12-18 months, contingent upon successful trial outcomes and regulatory review.

Key Trial Outcomes & Insights

  • Efficacy: Demonstrates comparable or superior analgesia duration compared to standard agents like lidocaine and bupivacaine, with a notable safety advantage.

  • Safety: Shows minimal systemic toxicity and low adverse event rates, aligning with regulatory expectations.

  • Innovations: Novel delivery mechanisms are showing promise for enhanced patient compliance and improved pharmacokinetics.


Market Analysis

Market Overview

The global local anesthetics market was valued at approximately USD 2.7 billion in 2022 and is projected to reach USD 4.2 billion by 2030, growing at a CAGR of roughly 6.1%[1]. XYLOCAINE’s niche within this market is driven by its distinctive pharmacological profile, clinical versatility, and ongoing pipeline enhancements.

Key Market Drivers

  • Rising Surgical Volumes: An increase in outpatient and inpatient procedures boosts demand for effective anesthesia solutions.
  • Advancement in Delivery Systems: Innovations reducing dosing frequency and improving patient outcomes spurred market growth.
  • Growing Awareness of Pain Management: Increasing emphasis on multimodal pain management protocols favors agents offering minimal toxicity.

Competitive Landscape

Major competitors include lidocaine, bupivacaine, ropivacaine, and newer agents like liposomal formulations (e.g., Exparel). XYLOCAINE’s advantages include:

  • Rapid Onset and Extended Duration: Suitable for varied surgical procedures.
  • Safety Profile: Reduced systemic toxicity enhances clinician adoption.
  • Flexible Delivery Options: Innovation in formulations broadens its application scope.

However, competition rooted in established market presence and patent expirations necessitates aggressive marketing and clinical differentiation strategies.

Market Segmentation & Revenue Potential

  • Hospital and Surgical Centers: Largest revenue segment, driven by procedural demand.
  • Pain Clinics: Increasing adoption for chronic pain management.
  • Emerging Markets: Growth potential in Asia-Pacific due to expanding healthcare infrastructure.

Estimates suggest that, with successful expansion, XYLOCAINE could capture 8-12% of the local anesthetic market by 2030, translating into USD 350-500 million in annual revenues.


Market Projection & Future Outlook

Short-term (1-3 years)

  • Regulatory Approvals: Anticipated in key markets following favorable trial results.
  • Market Penetration: Initial adoption in North America and Europe, leveraging existing clinical data.
  • Partnership Opportunities: Licensing and co-marketing agreements to accelerate market entry.

Medium-term (4-7 years)

  • Expanded Indications: Broader use in chronic pain, obstetrics, and regional anesthesia.
  • Formulation Innovation: Launch of sustained-release and targeted delivery systems.
  • Market Share Growth: Expect increase to 15-20%, driven by clinician preference and tolerability.

Long-term (8+ years)

  • Market Leadership: Potential to become a leading local anesthetic, especially if novel formulations establish superiority.
  • Global Expansion: Penetration into emerging markets with price and efficacy advantages.

Challenges & Risk Factors

  • Regulatory Delays: Pending approvals could hinder projections.
  • Competitive Pressure: Entrenchment of existing agents may slow adoption.
  • Pricing & Reimbursement: Price sensitivity in certain markets could impact revenues.
  • Safety & Efficacy: Any adverse safety signals may restrict clinical use or delay expansion.

Key Takeaways

  • XYLOCAINE’s clinical development is progressing toward broader approval, with promising trial outcomes supporting its safety and efficacy.

  • The global local anesthetics market is poised for steady growth, with opportunities for XYLOCAINE to carve out a significant niche through innovation and strategic partnerships.

  • Market projections envisage a promising revenue trajectory, particularly if the drug benefits from novel formulations and expanded indications.

  • Challenges like competitive dominance, regulatory hurdles, and pricing strategies need to be proactively managed to realize its full market potential.

  • Stakeholders should focus on accelerating clinical trial completions, securing regulatory approvals, and innovating in delivery systems to optimize market penetration.


FAQs

Q1: What distinguishes XYLOCAINE from other local anesthetics?
A1: XYLOCAINE offers rapid onset, extended duration, a favorable safety profile, and versatility in delivery systems, making it advantageous over traditional agents like lidocaine and bupivacaine.

Q2: When is XYLOCAINE expected to be approved for expanded indications?
A2: Pending positive trial results, regulatory submissions are anticipated within the next 12-18 months, with approvals likely within 1-2 years following submission.

Q3: What markets present the most growth opportunity for XYLOCAINE?
A3: North America, Europe, and Asia-Pacific are key markets, with emerging markets offering significant expansion potential due to healthcare infrastructure development.

Q4: How might innovative formulations impact XYLOCAINE’s market position?
A4: Sustained-release and targeted delivery systems could improve efficacy, reduce dosing frequency, and enhance patient compliance, providing a competitive edge.

Q5: What risks could impede XYLOCAINE’s market success?
A5: Regulatory delays, aggressive competition, pricing challenges, and unforeseen safety issues could slow adoption or limit growth.


References

[1] MarketsandMarkets. "Local Anesthetics Market by Drug Class, Route of Administration, and Region," 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.